Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm post market study of patients to assess fusion in one or
multiple continuous levels of the lumbosacral spine (L1-S1) using ViviGen Cellular Bone
Matrix. All subjects will be followed out to 24 months for final assessment.